Searchable abstracts of presentations at key conferences in endocrinology

ea0075o09 | Obesity, metabolism & miscellaneous endocrinology | EYES2021

Characterization and oncogenic role of the somatostatin receptor splicing variant SST5TMD4 in human high-grade astrocytomas

Garcia-Garcia Miguel E. , Fuentes-Fayos Antonio C. , Peel Annabel , Blanco-Acevedo Cristobal , Solivera Juan , Castano Justo P. , Gahete Manuel D. , Luque Raul M.

Background: Gliomas are the most common primary brain tumor, being astrocytomas a subset of malignant gliomas graded on a scale of I to IV. Grade-IV astrocytomas (glioblastoma multiforme; GBM) are the most malignant and aggressive type. Current standard treatments are ineffective, being their average postoperative survival of 12-16 months. Therefore, there is a clear need for the identification of novel therapeutic targets to treat this pathology. In this context, the truncate...

ea0081p132 | Endocrine-Related Cancer | ECE2022

Somatostatin receptor splicing variant SST5TMD4 overexpression in glioblastoma is associated to poor survival, increased aggressiveness features and somatostatin analogs resistance

Perez Gomez Jesus , Fuentes-Fayos Antonio C. , G-Garcia Miguel E. , Peel Annabel , Blanco Acevedo Cristobal , Solivera Vela Juan , Ibanez Costa Alejandro , David Gahete Ortiz Manuel , Castano Justo P. , Luque Raul M.

Glioblastoma (GBM; grade IV astrocytoma) is the one of the most malignant and lethal endocrine-related cancers worldwide. Current standard treatment consists of surgery followed by radiotherapy and/or chemotherapy; however, this is only a palliative approach with a mean post-operative survival of scarcely ~12-15 months. Therefore, the identification of novel therapeutic targets to treat this devastating pathology is urgently needed. In this context, the truncated splicing-vari...